Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Prospective Cohort Study on Performance of Cerebrospinal Fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and Urine LAM LFA for Diagnosis of Tuberculous Meningitis in Zambia.

Siddiqi OK, Birbeck GL, Ghebremichael M, Mubanga E, Love S, Buback C, Kosloff B, Ayles H, Atadzhanov M, Dheda K, Koralnik IJ.

J Clin Microbiol. 2019 Jul 26;57(8). pii: e00652-19. doi: 10.1128/JCM.00652-19. Print 2019 Aug.

PMID:
31189584
2.

Clinical and genetic analysis of spinocerebellar ataxia type 7 (SCA7) in Zambian families.

Atadzhanov M, Smith DC, Mwaba MH, Siddiqi OK, Bryer A, Greenberg LJ.

Cerebellum Ataxias. 2017 Nov 29;4:17. doi: 10.1186/s40673-017-0075-5. eCollection 2017.

3.

Exposure to biomass smoke as a risk factor for oesophageal and gastric cancer in low-income populations: A systematic review.

Kayamba V, Heimburger DC, Morgan DR, Atadzhanov M, Kelly P.

Malawi Med J. 2017 Jun;29(2):212-217. Review.

4.

HIV infection, hypercoagulability and ischaemic stroke in adults at the University Teaching Hospital in Zambia: a case control study.

Zimba S, Ntanda PM, Lakhi S, Atadzhanov M.

BMC Infect Dis. 2017 May 18;17(1):354. doi: 10.1186/s12879-017-2455-0.

5.

Developing a successful global neurology program.

Siddiqi OK, Brown M, Cooper C, Atadzhanov M, Lakhi S, Koralnik IJ.

Ann Neurol. 2017 Feb;81(2):167-170. doi: 10.1002/ana.24863. Review. No abstract available.

PMID:
28019673
6.

Evidence for a common founder effect amongst South African and Zambian individuals with Spinocerebellar ataxia type 7.

Smith DC, Atadzhanov M, Mwaba M, Greenberg LJ.

J Neurol Sci. 2015 Jul 15;354(1-2):75-8. doi: 10.1016/j.jns.2015.04.053. Epub 2015 May 9.

PMID:
26003224
7.

Lumbar puncture refusal in sub-Saharan Africa: A call for further understanding and intervention.

Thakur KT, Mateyo K, Hachaambwa L, Kayamba V, Mallewa M, Mallewa J, Nwazor EO, Lawal T, Mallum CB, Atadzhanov M, Boulware DR, Birbeck GL, Siddiqi OK.

Neurology. 2015 May 12;84(19):1988-90. doi: 10.1212/WNL.0000000000001561. No abstract available.

8.

Reexamining epilepsy-associated stigma: validation of the Stigma Scale of Epilepsy in Zambia.

Elafros MA, Bowles RP, Atadzhanov M, Mbewe E, Haworth A, Chomba E, Birbeck GL.

Qual Life Res. 2015 Jun;24(6):1483-9. doi: 10.1007/s11136-014-0868-4. Epub 2014 Nov 22.

9.

Frequency of APOE, MTHFR and ACE polymorphisms in the Zambian population.

Atadzhanov M, Mwaba MH, Mukomena PN, Lakhi S, Mwaba P, Rayaprolu S, Meschia JF, Ross OA.

BMC Res Notes. 2014 Mar 28;7:194. doi: 10.1186/1756-0500-7-194.

10.

Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults.

Siddiqi OK, Ghebremichael M, Dang X, Atadzhanov M, Kaonga P, Khoury MN, Koralnik IJ.

Clin Infect Dis. 2014 Jun;58(12):1771-7. doi: 10.1093/cid/ciu191. Epub 2014 Mar 25.

11.

Association of the APOE, MTHFR and ACE Genes Polymorphisms and Stroke in Zambian Patients.

Atadzhanov M, Mwaba MH, Mukomena PN, Lakhi S, Rayaprolu S, Ross OA, Meschia JF.

Neurol Int. 2013 Nov 11;5(4):e20. doi: 10.4081/ni.2013.e20. eCollection 2013.

12.

Stigma and psychiatric morbidity among mothers of children with epilepsy in Zambia.

Elafros MA, Sakubita-Simasiku C, Atadzhanov M, Haworth A, Chomba E, Birbeck GL.

Int Health. 2013 Dec;5(4):288-94. doi: 10.1093/inthealth/iht028. Epub 2013 Nov 8.

13.

Neurological letter from Zambia.

Siddiqi OK, Atadzhanov M.

Pract Neurol. 2013 Aug;13(4):281-5. doi: 10.1136/practneurol-2013-000558. Epub 2013 Apr 4. No abstract available.

PMID:
23559423
14.

Peer support groups as an intervention to decrease epilepsy-associated stigma.

Elafros MA, Mulenga J, Mbewe E, Haworth A, Chomba E, Atadzhanov M, Birbeck GL.

Epilepsy Behav. 2013 Apr;27(1):188-92. doi: 10.1016/j.yebeh.2013.01.005. Epub 2013 Mar 1.

15.

Emerging subspecialties in neurology: global health.

Siddiqi OK, Koralnik IJ, Atadzhanov M, Birbeck GL.

Neurology. 2013 Feb 19;80(8):e78-80. doi: 10.1212/WNL.0b013e31828250e9. No abstract available.

16.

The cost of implementing a nationwide program to decrease the epilepsy treatment gap in a high gap country.

Birbeck GL, Chomba E, Mbewe E, Atadzhanov M, Haworth A, Kansembe H.

Neurol Int. 2012 Oct 5;4(3):e14. doi: 10.4081/ni.2012.e14.

17.

Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.

Yonova-Doing E, Atadzhanov M, Quadri M, Kelly P, Shawa N, Musonda ST, Simons EJ, Breedveld GJ, Oostra BA, Bonifati V.

Parkinsonism Relat Disord. 2012 Jun;18(5):567-71. doi: 10.1016/j.parkreldis.2012.02.018. Epub 2012 Mar 24.

PMID:
22445250
18.

Evidence-Based Guidelines for EEG Utilization at the University Teaching Hospital (UTH).

Birbeck GL, Chomba E, Atadzhanov M, Haworth A, Mbewe E, Mpabalwani EM; the Neurologic & Psychiatric Society of Zambia (NPSZ).

Med J Zambia. 2011;38(3). pii: http://www.mjz.co.zm/content/neurological-psychiatric-society-zambias-evidence-based-guidelines-eeg-utilization. No abstract available.

19.

Epilepsy-associated stigma in Zambia: what factors predict greater felt stigma in a highly stigmatized population?

Atadzhanov M, Haworth A, Chomba EN, Mbewe EK, Birbeck GL.

Epilepsy Behav. 2010 Nov;19(3):414-8. doi: 10.1016/j.yebeh.2010.08.017. Epub 2010 Sep 17.

20.

The current availability of antiepileptic drugs in Zambia: implications for the ILAE/WHO "out of the shadows" campaign.

Chomba EN, Haworth A, Mbewe E, Atadzhanov M, Ndubani P, Kansembe H, Birbeck GL.

Am J Trop Med Hyg. 2010 Sep;83(3):571-4. doi: 10.4269/ajtmh.2010.10-0100.

21.

Evaluating the diagnostic capacity of a single-question neuropathy screen (SQNS) in HIV positive Zambian adults.

Kandiah PA, Atadzhanov M, Kvalsund MP, Birbeck GL.

J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1380-1. doi: 10.1136/jnnp.2009.183210. Epub 2010 Jun 11.

PMID:
20543182
22.

The spectrum of neurological disorders in a Zambian tertiary care hospital.

Siddiqi OK, Atadzhanov M, Birbeck GL, Koralnik IJ.

J Neurol Sci. 2010 Mar 15;290(1-2):1-5. doi: 10.1016/j.jns.2009.12.022. Epub 2010 Jan 12.

23.

Women's experiences living with epilepsy in Zambia.

Birbeck GL, Chomba E, Atadzhanov M, Mbewe E, Haworth A.

Am J Trop Med Hyg. 2008 Aug;79(2):168-72.

24.

The socioeconomic status of children with epilepsy in Zambia: implications for long-term health and well-being.

Chomba E, Haworth A, Atadzhanov M, Mbewe E, Birbeck GL.

Epilepsy Behav. 2008 Nov;13(4):620-3. doi: 10.1016/j.yebeh.2008.06.008. Epub 2008 Aug 12.

25.

Re: Upper limb tremor induced by peripheral nerve injury.

Atadzhanov M, Mwaba P.

Neurology. 2007 Sep 25;69(13):1381; author reply 1381. No abstract available.

PMID:
17893300
26.

Epilepsy-related knowledge, attitudes, and practices among Zambian police officers.

Mbewe E, Haworth A, Atadzhanov M, Chomba E, Birbeck GL.

Epilepsy Behav. 2007 May;10(3):456-62. Epub 2007 Mar 23.

27.

The social and economic impact of epilepsy in Zambia: a cross-sectional study.

Birbeck G, Chomba E, Atadzhanov M, Mbewe E, Haworth A.

Lancet Neurol. 2007 Jan;6(1):39-44.

28.

Zambian health care workers' knowledge, attitudes, beliefs, and practices regarding epilepsy.

Chomba EN, Haworth A, Atadzhanov M, Mbewe E, Birbeck GL.

Epilepsy Behav. 2007 Feb;10(1):111-9. Epub 2006 Oct 18.

29.

Zambian teachers: what do they know about epilepsy and how can we work with them to decrease stigma?

Birbeck GL, Chomba E, Atadzhanov M, Mbewe E, Haworth A.

Epilepsy Behav. 2006 Sep;9(2):275-80. Epub 2006 Jul 31.

PMID:
16877045
30.

Knowledge, attitudes, behaviors, and practices regarding epilepsy among Zambian clerics.

Atadzhanov M, Chomba E, Haworth A, Mbewe E, Birbeck GL.

Epilepsy Behav. 2006 Aug;9(1):83-8. Epub 2006 May 19.

PMID:
16713361
31.

Study of familial Parkinson's disease in Russia, Uzbekistan, and Zambia.

Atadzhanov M, Zumla A, Mwaba P.

Postgrad Med J. 2005 Feb;81(952):117-21.

32.

Dopamine D2 receptor and obesity.

Atadzhanov M.

Lancet. 2001 Jun 9;357(9271):1883. No abstract available.

PMID:
11417578
33.

[Phospholipid spectrum in target organs in chronic stress].

Atadzhanov MA, Bashirova NS, Usmankhodzhaeva AI, Sadykova GR, Tadzhibaeva KhKh.

Patol Fiziol Eksp Ter. 1995 Jul-Sep;(3):46-8. Russian.

PMID:
7501437
34.

Features of the parkinsonian syndrome induced experimentally by a deficit of nigrostriatal dopamine and stimulation of cholinergic neurons of the caudate nuclei.

Kryzhanovskii GN, Atadzhanov MA, Voronina TA, Nerobkova LN.

Neurosci Behav Physiol. 1994 Nov-Dec;24(6):485-8. No abstract available.

PMID:
7715769
35.

[Serotonin antibodies and their possible role in parkinsonism].

Kryzhanovskiĭ GN, Man'kovskiĭ NB, Karaban' IN, Magaeva SV, Trekova NA, Vetrilé LA, Basharova LA, Atadzhanov MA, Golubev KM.

Zh Nevrol Psikhiatr Im S S Korsakova. 1994;94(5):21-6. Russian.

PMID:
7900444
36.

[Role of the striatal serotoninergic apparatus in Parkinsonian syndrome].

Kryzanovskiĭ GN, Magaeva SV, Trekova NA, Vetrilé LA, Basharova LA, Atadzhanov MA.

Biull Eksp Biol Med. 1993 May;115(5):466-9. Russian.

PMID:
8043821
37.

[The effect of bromocryptin on rotational activity in rats].

Omel'nitskiĭ PP, Sokolov SIa, Kucherianu VG, Atadzhanov MA.

Eksp Klin Farmakol. 1993 Mar-Apr;56(2):13-6. Russian.

PMID:
8348026
38.

[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].

Kryzhanovskiĭ GN, Atadzhanov MA, Voronina TA, Nerobkova LN.

Zh Nevrol Psikhiatr Im S S Korsakova. 1993;93(6):3-7. Russian.

PMID:
8160497
39.

[Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].

Atadzhanov MA.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(4):117-21. Review. Russian. No abstract available.

PMID:
1650080
40.

[Effects of difenin on experimental parkinsonian syndrome].

Kryzhanovskiĭ GN, Atadzhanov MA, Kucherianu VG.

Biull Eksp Biol Med. 1990 Sep;110(9):242-4. Russian.

PMID:
2268704
41.

[Effects of substance P on experimental parkinsonian syndrome].

Kryzhanovskiĭ GN, Atadzhanov MA, Kucherianu VG.

Biull Eksp Biol Med. 1989 Oct;108(10):404-7. Russian.

PMID:
2480824
42.

[Parkinson syndrome after administration of acetylcholine into the caudate nuclei].

Kryzhanovskiĭ GN, Atadzhanov MA, Voronina TA, Nerobkova LN.

Biull Eksp Biol Med. 1989 May;107(5):522-5. Russian.

PMID:
2736276
43.

[Clinico-electroencephalographic indices of the parkinsonian syndrome induced by MPP+ in rats].

Kryzhanovski? GN, Atadzhanov MA, Voronina TA, Nerobkova LN, Zagorevski VA.

Biull Eksp Biol Med. 1989 Feb;107(2):147-50. Russian.

PMID:
2784332
44.

[EEG changes and symptomatic parkinsonism after intracaudate administration of dopamine antibodies].

Kryzhanovskiĭ GN, Atadzhanov MA, Magaeva SV, Basharova LA, Vetrilé LA.

Biull Eksp Biol Med. 1989 Jan;107(1):13-6. Russian.

PMID:
2914165
45.

[Lipid peroxidation in the caudate nuclei in experimental parkinsonian syndrome].

Kucherianu VG, Atadzhanov MA, Nikushkin EV, Zagorevskiĭ VA, Sharkova LM.

Biull Eksp Biol Med. 1989 Jan;107(1):39-41. Russian.

PMID:
2783652
46.

[Experimental parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine].

Kryzhanovskiĭ GN, Atadzhanov MA, Zagorevskiĭ VA, Sharkova LM, Voronina TA.

Biull Eksp Biol Med. 1988 Apr;105(4):397-401. Russian.

PMID:
3258764
47.

[Modeling parkinsonism (review)].

Atadzhanov M.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1982;82(3):110-9. Review. Russian. No abstract available.

PMID:
6805182
48.

[Diabetes mellitus in families with Parkinson's disease].

Atadzhanov M.

Klin Med (Mosk). 1973 May;51(5):87-91. Russian. No abstract available.

PMID:
4768975
49.

[The role of heredity in Parkinson's disease].

Atadzhanov M.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1973;73(2):195-9. Russian. No abstract available.

PMID:
4743268
50.

[Hereditary aspects of Parkinson's disease (review of the literature)].

Atadzhanov M.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1973;73(6):919-26. Review. Russian. No abstract available.

PMID:
4584983

Supplemental Content

Loading ...
Support Center